Brief: Karyopharm Therapeutics Q2 Net Income USD 23.792 Million
06/08/2024 12:30
Aug 06 (Reuters) - Karyopharm Therapeutics Q2 operating income USD -28.12 million. * Q2 product revenue USD 28.032 million * Q2 operating expenses USD 70.906 million * outlook FY revenue USD 145-160 million
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview